logo

For the Inventor, By the Inventor

Edinburgh, United Kingdom

Nucana Plc


USPTO Granted Patents = 28

% Expired Patents = 7.1



Trademarks = 1

Forward Citations = 99

Loading Chart...
Loading Chart...

15 inventors (with patents filed for the assignee):

goldMedal Hugh Griffith (19 out of 19 patents)

silverMedal Christopher McGuigan (12 out of 38 patents)

bronzeMedal Gordon Kennovin (8 out of 8 patents)

4.  Magdalena Slusarczyk (8 out of 11 patents)

5.  Michaela Serpi (7 out of 8 patents)

6.  Venkata Lakshmi Narasimha Rao Dammalapati (5 out of 12 patents)

7.  Mani Bushan Kotala (5 out of 9 patents)

8.  Valentina Ferrari (5 out of 5 patents)

9.  Jan Balzarini (4 out of 35 patents)

10.  Blanka Gonczy (4 out of 7 patents)

11.  Paola Murziani (4 out of 7 patents)

12.  Carmen Jimenez Antunez (3 out of 3 patents)

13.  Fabrizio Pertusati (2 out of 4 patents)

14.  Chris Pepper (1 out of 2 patents)

15.  Chris McGuigan (1 out of 2 patents)


28 patents:

1. 12357652 - Formulations of phosphoramidate derivatives of nucleoside drugs (2025-07-15),
2. 12054511 - Synthesis of phosphate derivatives (2024-08-06),
3. 12054510 - 2' and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds (2024-08-06),
4. 11925658 - Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancer (2024-03-12),
5. 11897913 - Synthesis of 3′-deoxyadenosine-5′-O-[phenyl(benzyloxy-L-alaninyl)]phosphate (NUC-738) (2024-02-13),
6. 11786544 - Formulations of phosphoramidate derivatives of nucleoside drugs (2023-10-17),
7. 11707477 - Formulation comprising a gemcitabine-prodrug (2023-07-25),
8. 11629164 - Gemcitabine prodrugs (2023-04-18),
9. 11603382 - Diastereoselective synthesis of phosphate derivatives (2023-03-14),
10. 11560400 - Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds (2023-01-24),
11. 11559542 - Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer (2023-01-24),
12. 11414452 - Synthesis of phosphate derivatives (2022-08-16),
13. 11414451 - Floxuridine synthesis (2022-08-16),
14. 11400107 - Cancer treatments (2022-08-02),
15. 11377467 - Crystalline form of gemcitabine (2022-07-05),
Nucana Plc is a biopharmaceutical company based in Edinburgh, specializing in the development of innovative cancer therapies. The company focuses on advancing its proprietary technology platform, which aims to enhance the efficacy and safety of existing cancer treatments. Nucana's research is centered on transforming the treatment landscape for patients with cancer, leveraging its expertise in drug development and a commitment to addressing unmet medical needs in oncology.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Nucana Plc
28 Patents

#10 in Edinburgh

#637 in United Kingdom

#23,244 in the World

Edinburgh, GB
Edinburgh, United Kingdom

Nucana Plc

Forward Citations = 99

15 inventors:

goldMedal Hugh Griffith (19 out of 19 patents)

silverMedal Christopher McGuigan (12 out of 38 patents)

bronzeMedal Gordon Kennovin (8 out of 8 patents)

4.  Magdalena Slusarczyk (8 out of 11 patents)

5.  Michaela Serpi (7 out of 8 patents)

Please report any incorrect information to [email protected]
Loading…